Immuron (IMRN) Shares Outstanding (Weighted Average) (2016 - 2025)
Immuron's quarterly Shares Outstanding (Weighted Average) came in at $888.7 million in Q3 2025, little changed year-on-year from $885.0 million in Q3 2024, and up 1461.44% quarter-over-quarter from $56.9 million in Q2 2025.
Immuron has reported Shares Outstanding (Weighted Average) for 10 years, with the latest figure at $888.7 million in Q3 2025.
- For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) changed 0.42% year-over-year to $888.7 million; the trailing twelve-month figure through Sep 2025 stood at $888.7 million (changed 0.42% YoY), and the FY2025 full-year result was $888.7 million, changed 0.42% from the prior year.
- Shares Outstanding (Weighted Average) for Q3 2025 stood at $888.7 million, up from $56.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $888.7 million in Q3 2025, with the low at $56.9 million in Q2 2025.
- Average Shares Outstanding (Weighted Average) over 5 years is $391.1 million, with a median of $62.9 million recorded in 2021.
- Peak annual rise in Shares Outstanding (Weighted Average) reached 1337.97% in 2023, while the deepest fall reached 93.32% in 2023.
- Tracing IMRN's Shares Outstanding (Weighted Average) over 5 years: stood at $64.4 million in 2021, then slipped by 9.74% to $58.1 million in 2022, then soared by 890.82% to $575.7 million in 2023, then sank by 89.94% to $57.9 million in 2024, then soared by 1434.09% to $888.7 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $888.7 million (Q3 2025), $56.9 million (Q2 2025), and $57.9 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | 888.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 888.73 Mn |
| Jun 30, 2025 | 56.92 Mn |
| Dec 31, 2024 | 57.93 Mn |
| Sep 9, 2024 | 885.04 Mn |
| Jun 30, 2024 | 58.33 Mn |
| Dec 31, 2023 | 575.71 Mn |
| Sep 28, 2023 | 57.97 Mn |
| Aug 30, 2023 | 884.36 Mn |
| Jun 30, 2023 | 59.11 Mn |
| Dec 31, 2022 | 58.10 Mn |
| Aug 31, 2022 | 61.50 Mn |
| Jun 30, 2022 | 884.36 Mn |
| Dec 31, 2021 | 64.37 Mn |
| Jun 30, 2021 | 883.61 Mn |
| Sep 1, 2020 | 62.43 Mn |
| Jun 30, 2020 | 115.61 Mn |
| Dec 31, 2019 | 624.27 Mn |
| Jun 30, 2019 | 101.39 Mn |
| Dec 31, 2018 | 58.37 Mn |
| Aug 30, 2018 | 58.37 Mn |
| Jun 30, 2018 | 44.19 Mn |
| Dec 31, 2017 | 41.96 Mn |
| Sep 28, 2017 | 42.30 Mn |
| Aug 31, 2017 | 53.63 Mn |
| Jun 30, 2017 | 79.53 Mn |
| Dec 31, 2016 | 34.41 Mn |
| Jun 30, 2016 | 57.07 Mn |